Stock listing

BOATS:RXRX Recursion Pharmaceuticals, Inc. Stock

US listing (BOATS) of Recursion Pharmaceuticals, Inc. · home listing NASDAQ:RXRX

Follow Recursion Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RXRX

$2.45 USD -0.38 (-13.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RXRX

Past year -36.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.44 – $2.76 USDNov 20, 2026
Volume
29.80M sharesNov 20, 2026
Market cap
$1.53B USDAt the close on Nov 20, 2026 · price × 622.8M shares outstanding
52-week range
$2.44 – $5.24 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$89.94M USDMedian day 20.39M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Recursion Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RXRX · Home$2.45 USD-0.375 (-13.3%)29,797,529$2.63$2.76$2.44$2.825Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RXRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.45-0.375-13.3%$2.63$2.76$2.4429,797,529
$2.825+0.105+3.9%$2.785$3.02$2.7741,127,675
$2.72-0.185-6.4%$2.945$2.945$2.5040,745,536
$2.905-0.28-8.8%$3.095$3.13$2.86519,603,924
$3.185-0.145-4.4%$3.33$3.34$3.1616,526,938
$3.33-0.26-7.2%$3.422$3.46$3.26520,388,676
$3.59+0.04+1.1%$3.685$3.72$3.5316,483,995
$3.55-0.255-6.7%$3.69$3.77$3.4719,080,002
$3.805+0.285+8.1%$3.52$3.87$3.4720,321,698
$3.52+0.02+0.6%$3.585$3.645$3.4815,484,291
$3.50-0.38-9.8%$3.79$3.795$3.4225,236,618
$3.88+0.20+5.4%$3.83$4.01$3.7220,545,054
$3.68-0.15-3.9%$3.855$4.08$3.6520,658,666
$3.83-0.20-5.0%$4.125$4.17$3.7822,444,255
$4.03-0.21-5.0%$4.05$4.16$3.78524,357,781
$4.24-0.11-2.5%$4.24$4.515$4.1520,566,825
$4.35+0.30+7.4%$4.00$4.43$3.99528,353,942
$4.05+0.25+6.6%$3.81$4.145$3.7322,100,545
$3.80+0.10+2.7%$3.72$3.86$3.6416,055,282
$3.70+0.12+3.4%$3.52$3.70$3.4519,038,600
$3.58-0.06-1.6%$3.54$3.68$3.48517,735,700
$3.64-0.02-0.5%$3.66$3.76$3.5619,356,500
$3.66+0.05+1.4%$3.555$3.67$3.4720,925,100
$3.61+0.145+4.2%$3.53$3.69$3.4830,009,600
$3.465-0.695-16.7%$4.11$4.185$3.4440,724,300
$4.16+0.42+11.2%$3.65$4.41$3.5362,870,100
$3.74-0.095-2.5%$3.72$3.91$3.6618,783,700
$3.835-0.175-4.4%$4.01$4.05$3.8219,764,300
$4.01-0.35-8.0%$4.31$4.365$3.9123,785,300
$4.36+0.41+10.4%$4.015$4.43$3.8935,501,300
$3.95-0.32-7.5%$4.19$4.20$3.7930,898,400
$4.27-0.36-7.8%$4.505$4.60$4.2340,730,500
$4.63-0.15-3.1%$4.81$5.19$4.39571,106,000
$4.78+0.66+16.0%$4.16$4.935$4.0667,278,700
$4.12+0.05+1.2%$4.18$4.27$4.0118,840,000
$4.07-0.06-1.5%$4.07$4.17$3.9617,484,100
$4.13+0.10+2.5%$4.09$4.29$3.9832,785,900
$4.03+0.33+8.9%$3.73$4.04$3.72321,564,000
$3.70-0.04-1.1%$3.69$3.84$3.66513,058,800
$3.74-0.15-3.9%$3.89$3.90$3.7010,481,300
$3.89+0.19+5.1%$3.65$3.90$3.6119,338,300
$3.70-0.35-8.6%$4.03$4.09$3.6623,670,600
$4.05+0.08+2.0%$4.00$4.16$3.9040,460,400
$3.97+0.14+3.7%$3.92$4.015$3.8337,728,700
$3.83+0.29+8.2%$3.54$3.83$3.5044,325,600
$3.54+0.35+11.0%$3.28$3.59$3.2628,251,200
$3.19-0.05-1.5%$3.26$3.31$3.1614,813,900
$3.24-0.17-5.0%$3.37$3.37$3.2211,881,300
$3.41+0.21+6.6%$3.19$3.455$3.1817,102,500
$3.20+0.04+1.3%$3.21$3.25$3.158,034,100
$3.16-0.055-1.7%$3.14$3.25$3.1010,617,000
$3.215-0.225-6.5%$3.42$3.45$3.2114,198,900
$3.44-0.19-5.2%$3.58$3.59$3.4314,990,200
$3.63+0.19+5.5%$3.415$3.70$3.4129,039,100
$3.44+0.06+1.8%$3.435$3.45$3.2913,746,100
$3.38+0.05+1.5%$3.34$3.489$3.28514,052,700
$3.33-0.07-2.1%$3.34$3.38$3.289,991,900
$3.40+0.06+1.8%$3.305$3.41$3.2513,903,400
$3.34-0.10-2.9%$3.40$3.45$3.3110,560,600
$3.44-0.05-1.4%$3.515$3.55$3.4210,986,800
$3.49-0.07-2.0%$3.51$3.55$3.4312,978,400
$3.56+0.31+9.5%$3.27$3.59$3.2622,516,700
$3.25-0.25-7.1%$3.42$3.44$3.21515,155,100
$3.50+0.16+4.8%$3.39$3.63$3.3722,898,500
$3.34-0.16-4.6%$3.40$3.46$3.2721,453,700
Ticker
BOATS:RXRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Recursion Pharmaceuticals, Inc. news

Recursion Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 122 in all · newest Nov 18, 2026 · oldest 2021
Calls
10 calls with a replay · 10 with a transcript · latest Nov 3, 2026
Decks
48 decks · latest Nov 3, 2026

Where Recursion Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RXRX · Home listingNASDAQUnited StatesUSD
BMV:RXRXBMVMexicoMXN
BOATS:RXRX · This pageBOATSUnited StatesUSD
gettex:A3CM1CgettexGermanyEUR
BIVA:RXRXBIVAMexicoMXN
BX Swiss:RXRXBX SwissSwitzerlandCHF
Stuttgart:8RLStuttgartGermanyEUR

Valuation

EV/sales 14.5× against a median of 52.7×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$987.7M USD
P/E
Loss
EV/sales
14.5×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.7×
Gross margin
29.2%
Operating margin
−725.4%
Net margin
−697.1%
Debt to equity
0.0×
Beta vs S&P 500
2.83

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Recursion Pharmaceuticals, Inc. · NASDAQ:RXRXUS$1.53BUS$987.7Mn/a14.5×n/a1.7×−697.1%0.0×2.83
Zenas BioPharma, Inc. · NASDAQ:ZBIOUS$1.62BUS$1.26Bn/a114×n/a7.6×n/a1.1×1.05
Hitgen Inc. Class A · SSE:688222US$1.56BUS$1.44B66.5×13.6×n/a6.5×22.1%0.2×n/a
Alvotech · NASDAQ:ALVOUS$1.47BUS$2.78Bn/a5.7×31.4×n/a−36.5%n/a0.90
ABL Bio, Inc. · KRX:298380US$1.47BUS$1.34Bn/a52.7×n/a11.5×−229.4%0.0×n/a
PELL Bio-Med Technology Co Ltd · TWSE:6949US$1.46BUS$1.40Bn/a1,591×n/a18.7×n/a0.1×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.4×n/a2.4×−593.9%0.2×n/a
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
Voronoi, Inc. · KRX:310210US$1.44BUS$1.39Bn/an/an/a27.9×n/a0.5×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Median of the othersUS$1.46BUS$1.37B66.5×52.7×31.4×6.5×−61.0%0.1×1.05

Forecasts

1 strong buy · 2 buy · 4 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
7.32 USD · Analysts' mean
EPS, year to Dec 2026
-0.88 · 8 analysts
Revenue, year to Dec 2026
40.32M · 7 analysts

Team and board

Officers

OfficerRole
Najat KhanCEO and President
Ben TaylorChief Financial Officer & President Recursion UK
Nathan HatfieldChief Legal Officer & Corporate Secretary
Sid JainSVP of Clinical Development & Data Science
Ben MabeyChief Technology Officer
David HallettChief Scientific Officer
Erica FoxChief People and Impact Officer
Matt KinnChief Business Officer
Ryan KellyChief Communications Officer
Vicki GoodmanChief Medical Officer

Board

DirectorRole
Fred HassanChair of the Board
Blake BorgesonBoard Member
Dean LiBoard Member
Elaine SunBoard Member
Franziska MichorBoard Member
Namandjé BumpusBoard Member
Robert HershbergBoard Member
Zachary BogueBoard Member
Zavain DarBoard Member

Events

Results days

QuarterResultsShare move
Q3 2026Nov 2, 2026 · After close−3.9%
Q2 2026Aug 5, 2026 · Before open−4.2%
Q1 2026May 6, 2026 · Before open+1.8%
Q4 2025Feb 25, 2026+6.8%
Q3 2025Nov 5, 2025 · Before open−0.8%
Q2 2025Aug 5, 2025 · Before open−4.7%
Q1 2025May 5, 2025 · Before open−16.6%
Q4 2024Feb 25, 2025 · Before open−9.6%
Q3 2024Nov 6, 2024 · After close−0.6%
Q2 2024Aug 8, 2024 · Before open+4.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−0.5%
Q4 2023Feb 27, 2024 · After close−16.6%
Q3 2023Nov 9, 2023 · Before open−7.1%
Q2 2023Aug 8, 2023 · Before open+4.7%
Q1 2023May 8, 2023 · Before open+8.5%
Q4 2022Feb 27, 2023 · After close+5.6%
Q3 2022Nov 8, 2022 · After close+6.7%
Q2 2022Aug 9, 2022 · After close+12.0%
Q1 2022May 10, 2022 · After close−11.4%
Q4 2021Mar 23, 2022 · Before open−1.1%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings52 slidesNov 3, 2026
Investor Presentation (October 2026)Investor deck44 slidesOct 15, 2026
Corporate Update (August 2026)Corporate update66 slidesAug 5, 2026
Q2 2026 Earnings PresentationEarnings38 slidesAug 5, 2026
Q1 2026 Earnings PresentationEarnings34 slidesMay 6, 2026
Q1 2026 Earnings PresentationEarnings70 slidesMay 6, 2026
Q4 2025 Earnings PresentationEarnings44 slidesFeb 25, 2026
J.P. Morgan Healthcare Conference 2026Conference34 slidesJan 12, 2026
J.P. Morgan Healthcare Conference 2026Conference32 slidesJanuary 2026
Technical Presentation (December 2025)Technical42 slidesDec 8, 2025
All 48 decks
DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck49 slidesNov 5, 2025
Q3 2025 Earnings PresentationEarnings30 slidesNov 5, 2025
Q2 2025 Earnings PresentationEarnings32 slidesAug 5, 2025
Q2 2025 Earnings PresentationEarnings32 slidesAug 5, 2025
Investor Presentation (June 2025)Investor deck29 slidesJun 10, 2025
Q1 2025 Earnings PresentationEarnings54 slidesMay 5, 2025
Q1 2025 Earnings PresentationEarnings51 slidesMay 5, 2025
Q4 2024 Earnings PresentationEarnings85 slidesFeb 28, 2025
J.P. Morgan Healthcare Conference 2025Conference70 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck70 slidesNov 20, 2024
Q3 2024 Earnings PresentationEarnings90 slidesNov 6, 2024
Merger or Acquisition (October 2024)Merger or acquisition92 slidesOct 2, 2024
Merger or Acquisition (September 2024)Merger or acquisition92 slidesSep 3, 2024
Merger or Acquisition (August 2024)Merger or acquisition115 slidesAug 8, 2024
Merger or Acquisition (August 2024)Merger or acquisition93 slidesAug 8, 2024
Q2 2024 Earnings PresentationEarnings20 slidesAug 8, 2024
Investor Day (June 2024)Investor day179 slidesJun 24, 2024
Q1 2024 Earnings PresentationEarnings101 slidesMay 9, 2024
Q1 2024 Earnings PresentationEarnings15 slidesMay 9, 2024
Q4 2023 Earnings PresentationEarnings102 slidesFeb 27, 2024
FY2023 Earnings PresentationEarnings37 slidesFeb 27, 2024
Conference Presentation (January 2024)Conference104 slidesJan 8, 2024
Investor Presentation (December 2023)Investor deck97 slidesDec 20, 2023
Investor Presentation (October 2023)Investor deck94 slidesOct 2, 2023
Investor Presentation (September 2023)Investor deck94 slidesSep 5, 2023
Q2 2023 Earnings PresentationEarnings92 slidesAug 8, 2023
Investor Presentation (June 2023)Investor deck87 slidesJun 13, 2023
Q4 2022 Earnings PresentationEarnings85 slidesFeb 27, 2023
Investor Day (January 2023)Investor day143 slidesJan 25, 2023
JP Morgan Healthcare Conference 2023Conference37 slidesJan 10, 2023
Q3 2022 Earnings PresentationEarnings40 slidesNov 8, 2022
Investor Presentation (October 2022)Investor deck40 slidesOct 25, 2022
Q2 2022 Earnings PresentationEarnings34 slidesAug 9, 2022
Q1 2022 Earnings PresentationEarnings36 slidesMay 10, 2022
Q4 2021 Earnings PresentationEarnings34 slidesMar 23, 2022
Investor Presentation (January 2022)Investor deck34 slidesJan 10, 2022
Investor Presentation (November 2021)Investor deck45 slidesNov 10, 2021
Q2 2021 Earnings PresentationEarnings45 slidesSep 9, 2021

Open Decks

Financings

RaiseDate
Public offering of class A common stock
Announced: about US$200M · US$3.25 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), Goldman Sachs & Co. LLC (co-lead), Morgan Stanley & Co. LLC (co-lead), Evercore Group L.L.C. (co-lead), Needham & Company, LLC
Buyers: Janus Henderson Investors; Invus; Longaeva Partners; ARK Invest; Driehaus Capital Management
Use of proceeds: Advance highest-conviction programs and deliver on upcoming clinical milestones
Oct 15, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Apr 15, 2021.

Price
US$18.00 a share
Shares offered
24,242,424 shares of Class A common stock
Offering size
US$436.4 million
Underwriters' option
Up to 3,636,363 more shares
Underwriters
Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Company LLC, KeyBanc Capital Markets · In the order on the cover
Shares delivered
On or about Apr 20, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceJan 26, 2021
Filed publiclyMar 22, 2021
Amended twiceNewest Apr 15, 2021
Shares registered with an exchangeApr 12, 2021
Declared effective by the SECApr 15, 2021
Final prospectus, with the priceApr 16, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Apr 16, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue74.7M58.8M44.6M39.8M10.2M3.96M2.32M
Cost of revenue71.0M45.2M42.6M48.3M00
Gross profit3.73M13.6M1.99M-8.43M10.2M3.96M
Research and development475.3M314.4M241.2M155.7M135.3M63.3M45.8M
Operating income-648.1M-479.0M-350.1M-245.7M-182.8M-84.6M-62.4M
Depreciation and amortization83.7M36.5M24.4M11.8M8.40M3.94M2.49M
EBITDA-564.4M-442.5M-325.7M-234.0M-174.4M-80.7M-60.0M
Interest expense1.81M1.57M97.0K55.0K2.95M1.36M635.0K
Income before tax-644.9M-464.8M-332.1M-239.5M-186.5M
Income tax-136.0K-1.13M-4.06M0000
Net income-644.8M-463.7M-328.1M-239.5M-186.5M-87.0M-61.9M
Earnings per share, basic-1.44-1.69-1.58-1.36-1.49-3.99-2.87
Earnings per share, diluted-1.44-1.69-1.58-1.36-1.49-3.99-2.87

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents743.3M594.4M391.6M549.9M285.1M262.1M75.2M
Short-term investments0231.4M0
Receivables034.0K156.0K
Current assets812.8M714.3M438.1M569.8M534.7M266.4M
Property, plant and equipment103.9M141.1M86.5M88.2M64.7M26.0M
Goodwill162.2M148.9M52.1M801.0K801.0K801.0K
Total assets1.47B1.45B653.7M701.3M610.3M298.6M
Accounts payable18.1M21.6M3.95M4.59M2.82M1.07M
Current liabilities147.7M187.5M93.2M100.3M46.7M23.1M
Long-term debt9.56M19.0M1.10M
Total debt9.09M8.43M41.0K723.0K
Total liabilities343.3M413.8M190.3M215.5M67.4M56.6M
Shareholders' equity1.13B1.03B463.4M485.8M542.9M-206.3M-124.3M
Shares outstanding528.2M396.8M234.3M191.0M170.3M22.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-371.8M-359.2M-287.8M-83.5M-158.6M-45.4M-57.0M
Capital spending-6.47M-13.7M-12.0M-37.1M-39.8M-5.83M-3.91M
Free cash flow-378.3M-372.9M-299.7M-120.6M-198.4M-51.2M-61.0M
Cash from investing-16.9M260.1M-10.2M193.2M-271.7M-8.74M-3.91M
Cash from financing521.5M304.1M140.1M154.3M458.5M246.1M120.4M
Change in cash150.9M201.6M-157.7M263.8M28.2M192.0M59.5M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
10-Q · Quarterly reportNov 2, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 2, 2026ResultsSEC
424B5 · ProspectusOct 15, 2026Offer documentSEC
8-K · Current reportOct 15, 2026ResultsSEC
424B5 · ProspectusOct 15, 2026Offer documentSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportSep 21, 2026Material contractSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 30, 2026Other filingsSEC
144 · Notice of proposed saleJul 29, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
144 · Notice of proposed saleJul 20, 2026Other filingsSEC
144 · Notice of proposed saleJul 17, 2026Other filingsSEC
144 · Notice of proposed saleJul 16, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 14, 2026Other filingsSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
144 · Notice of proposed saleJul 10, 2026Other filingsSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
144 · Notice of proposed saleJul 8, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
144 · Notice of proposed saleMay 7, 2026Other filingsSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 30, 2026Management or board changeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 25, 2026Management or board changeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
144 · Notice of proposed saleMar 23, 2026Other filingsSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
144 · Notice of proposed saleMar 17, 2026Other filingsSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 25, 2026Offer documentSEC
424B5 · ProspectusFeb 25, 2026Offer documentSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
8-K · Current reportFeb 25, 2026ResultsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 3, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
8-K · Current reportJan 12, 2026Current reportSEC
3 · Initial statement of ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Current reportSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
8-K · Current reportNov 26, 2025Current reportSEC
424B7 · ProspectusNov 26, 2025Offer documentSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
8-K · Current reportOct 29, 2025Current reportSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
144 · Notice of proposed saleOct 23, 2025Other filingsSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
144 · Notice of proposed saleOct 10, 2025Other filingsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
144 · Notice of proposed saleSep 25, 2025Other filingsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
144 · Notice of proposed saleSep 10, 2025Other filingsSEC
8-K/A · Current report, amendedAug 29, 2025FinancingSEC
424B7 · ProspectusAug 29, 2025Offer documentSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC

This page holds 200 of 996 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Recursion Pharmaceuticals, Inc.’s releases · as of Oct 26, 2026

Common shares
622,759,259
Fully diluted
622,759,259

Fully diluted

LineSharesAs of
Common shares622,759,259Oct 26, 2026

Share count over time

CountShares
Oct 26, 2026622,759,259

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard63.3M10.2%US$261MSep 30, 2026
BlackRock53.5M8.6%US$221MSep 30, 2026
ARK44.7M7.2%US$185MSep 30, 2026
State Street30M4.8%US$124MSep 30, 2026
Baillie Gifford & Co18.2M2.9%US$75.1MSep 30, 2026
Geode Capital13.9M2.2%US$57.5MSep 30, 2026
Softbank Group Corp.13.6M2.2%US$56.3MSep 30, 2026
Fidelity11.4M1.8%US$47.2MSep 30, 2026
UBS9.22M1.5%US$38.1MSep 30, 2026
MIC Capital Management UK LLP8.26M1.3%US$34.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Two Sigma7.95M1.3%US$32.8MSep 30, 2026
Morgan Stanley6.22M1.00%US$25.7MSep 30, 2026
Data Collective IV GP, LLC5.94M0.95%US$24.5MSep 30, 2026
T. Rowe Price5.73M0.92%US$23.6MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.4.94M0.79%US$20.4MSep 30, 2026
Amova Asset Management Americas, Inc.4.94M0.79%US$20.4MSep 30, 2026
GMT Capital Corp4.86M0.78%US$20.1MSep 30, 2026
Northern Trust4.82M0.77%US$19.9MSep 30, 2026
Schwab4.74M0.76%US$19.6MSep 30, 2026
Millennium4.04M0.65%US$16.7MSep 30, 2026
DCVC Opportunity Fund II GP, LLC3.95M0.63%US$16.3MSep 30, 2026
First Trust3.55M0.57%US$14.7MSep 30, 2026
Goldman Sachs3.21M0.52%US$13.3MSep 30, 2026
Citadel2.96M0.48%US$12.2MSep 30, 2026
Susquehanna2.9M0.47%US$12MSep 30, 2026
IQ EQ FUND MANAGEMENT (IRELAND) Ltd2.68M0.43%US$11.1MSep 30, 2026
Jump Financial, LLC2.5M0.40%US$10.3MSep 30, 2026
Sun Life2.39M0.38%US$9.87MSep 30, 2026
Bank of America2.29M0.37%US$9.46MSep 30, 2026
Marshall Wace, LLP2.07M0.33%US$8.55MSep 30, 2026
Nuveen1.91M0.31%US$7.9MSep 30, 2026
Quadrature Capital Ltd1.89M0.30%US$7.8MSep 30, 2026
BNY1.62M0.26%US$6.67MSep 30, 2026
Schonfeld Strategic Advisors LLC1.04M0.17%US$4.29MSep 30, 2026
Swiss National Bank955K0.15%US$3.94MSep 30, 2026
XTX Topco Ltd955K0.15%US$3.94MSep 30, 2026
Comprehensive Financial Management LLC942K0.15%US$3.89MSep 30, 2026
Invesco913K0.15%US$3.77MSep 30, 2026
BNP Paribas794K0.13%US$3.28MSep 30, 2026
Creative Planning750K0.12%US$3.1MSep 30, 2026
Rafferty Asset Management, LLC721K0.12%US$2.98MSep 30, 2026
Man Group plc650K0.10%US$2.69MSep 30, 2026
Rhumbline Advisers624K0.10%US$2.58MSep 30, 2026
Manufacturers Life Insurance Company, The623K0.10%US$2.57MSep 30, 2026
Vestmark Advisory Solutions, Inc.620K0.10%US$2.56MSep 30, 2026
American Century594K0.10%US$2.45MSep 30, 2026
DWS586K0.09%US$2.42MSep 30, 2026
Rockefeller Capital Management L.P.573K0.09%US$2.37MSep 30, 2026
California State Teachers Retirement System561K0.09%US$2.32MSep 30, 2026
Balyasny Asset Management L.P.542K0.09%US$2.24MSep 30, 2026

This page holds 50 of 343 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF22.1M3.6%US$81.2MJun 30, 2026
ARK Innovation ETF20.3M3.3%US$60.8MJul 31, 2026
Vanguard Total Stock Market Index Fund15.8M2.5%US$58.1MJun 30, 2026
ARK Genomic Revolution ETF13.6M2.2%US$40.9MJul 31, 2026
iShares Russell 2000 ETF13.1M2.1%US$48.2MJun 30, 2026
Vanguard Small-Cap Index Fund11.4M1.8%US$41.9MJun 30, 2026
Vanguard Small-Cap Growth Index Fund6.56M1.1%US$24.1MJun 30, 2026
Vanguard Extended Market Index Fund6.01M0.96%US$22.1MJun 30, 2026
Fidelity Small Cap Index Fund5.59M0.90%US$16.8MJul 31, 2026
iShares Russell 2000 Value ETF4.37M0.70%US$16MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Strategic Equity Fund3.89M0.62%US$14.3MJun 30, 2026
iShares Biotechnology ETF3.34M0.54%US$12.2MJun 30, 2026
Vanguard U.S. Growth Fund3.26M0.52%US$11.7MMay 31, 2026
First Trust Nasdaq Artificial Intelligence and Robotics ETF3.04M0.49%US$11.2MJun 30, 2026
Fidelity Extended Market Index Fund2.65M0.42%US$9.5MMay 31, 2026
Schwab U.S. Small-Cap ETF2.48M0.40%US$8.89MMay 31, 2026
Vanguard Russell 2000 Index Fund2.36M0.38%US$8.46MMay 31, 2026
Vanguard Explorer Fund2.34M0.38%US$7.02MJul 31, 2026
BlackRock Advantage Small Cap Core Fund1.44M0.23%US$5.19MMay 29, 2026
Vanguard Strategic Small-Cap Equity Fund1.44M0.23%US$5.3MJun 30, 2026
Vanguard Health Care Index Fund1.33M0.21%US$4.77MMay 31, 2026
Schwab Small-Cap Index Fund1.24M0.20%US$3.73MJul 31, 2026
Fidelity Total Market Index Fund1M0.16%US$3.61MMay 31, 2026
Master Small Cap Index Series923K0.15%US$3.39MJun 30, 2026
Fidelity Series Total Market Index Fund785K0.13%US$2.82MMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares750K0.12%US$2.25MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF720K0.12%US$2.64MJun 30, 2026
Nuveen Small Cap Blend Index Fund679K0.11%US$2.04MJul 31, 2026
Fidelity Small Cap Value Index Fund650K0.10%US$2.39MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF592K0.10%US$2.17MJun 30, 2026
EQ/2000 Managed Volatility Portfolio557K0.09%US$2.04MJun 30, 2026
American Beacon ARK Transformational Innovation Fund537K0.09%US$1.97MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF497K0.08%US$1.49MJul 31, 2026
Nuveen ESG Small-Cap ETF458K0.07%US$1.37MJul 31, 2026
iShares Russell 2000 Growth ETF441K0.07%US$1.62MJun 30, 2026
Vanguard Russell 2000 Growth Index Fund432K0.07%US$1.55MMay 31, 2026
Small Company Growth Portfolio424K0.07%US$1.56MJun 30, 2026
Vanguard Total World Stock Index Fund420K0.07%US$1.26MJul 31, 2026
Nuveen Equity Index Fund392K0.06%US$1.18MJul 31, 2026
Schwab Total Stock Market Index Fund382K0.06%US$1.15MJul 31, 2026
LVIP State Street Small-Cap Index Fund363K0.06%US$1.33MJun 30, 2026
Avantis U.S. Small Cap Equity ETF356K0.06%US$1.28MMay 31, 2026
iShares ESG Aware MSCI USA Small-Cap ETF332K0.05%US$1.19MMay 31, 2026
Schwab U.S. Broad Market ETF314K0.05%US$1.13MMay 31, 2026
Fidelity Nasdaq Composite Index Fund308K0.05%US$1.1MMay 31, 2026
JPMorgan U.S. Small Company Fund282K0.05%US$1.04MJun 30, 2026
Fidelity ZERO Total Market Index Fund279K0.04%US$838KJul 31, 2026
BlackRock Advantage Small Cap Growth Fund277K0.04%US$1.02MJun 30, 2026
Vanguard Balanced Index Fund269K0.04%US$988KJun 30, 2026
Small Cap Index Fund259K0.04%US$950KJun 30, 2026

This page holds 50 of 175 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Borgeson Blake
Director
Sale40,000USD 3.88US$155KNov 3, 2026
Hershberg Robert
Director
Sale25,000USD 5.00US$125KOct 6, 2026
Borgeson Blake
Director
Sale50,000USD 4.84US$242KOct 6, 2026
Khan Najat
Director, Officer: CEO and President
Sale22,408USD 3.52US$78,876Sep 8, 2026
Borgeson Blake
Director
Sale30,000USD 3.34US$100KSep 1, 2026
Borgeson Blake
Director
Sale30,000USD 3.25US$97,500Aug 4, 2026
Borgeson Blake
Director
Sale40,000USD 3.96US$158KJul 7, 2026
Bumpus Namandje
Director
Sale3,963USD 3.18US$12,602Jun 18, 2026
Gibson Christopher
Director
Sale40,000USD 3.62US$145KJun 5, 2026
Khan Najat
Director, Officer: CEO and President
Sale23,588USD 3.58US$84,445Jun 5, 2026
All 18 trades
TradeTradeSharesPriceValueDate
Bumpus Namandje
Director
Sale4,386USD 3.54US$15,526Jun 3, 2026
Borgeson Blake
Director
Sale30,000USD 3.68US$110KJun 2, 2026
Gibson Christopher
Director
Sale40,000USD 3.08US$123KMay 22, 2026
Gibson Christopher
Director
Sale40,000USD 3.37US$135KMay 7, 2026
Borgeson Blake
Director
Sale30,000USD 3.52US$106KMay 5, 2026
Gibson Christopher
Director
Sale40,000USD 3.61US$144KApr 22, 2026
Borgeson Blake
Director
Sale30,000USD 3.10US$93,000Apr 7, 2026
Gibson Christopher
Director
Sale40,000USD 3.10US$124KApr 7, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.8.50%44.5MJun 30, 2026Schedule 13G
ARK Investment Management LLC8.36%44.7MSep 30, 2026Schedule 13G
Vanguard Portfolio Management LLC5.97%31.4MJun 30, 2026Schedule 13G
Yohan Kim5.86%268KApr 4, 2025Schedule 13G
State Street Corp5.60%30MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC5.09%26.7MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Hershberg
Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Adaptive Biotechnologies Corporation (Board Member · Since at least Jun 26, 2019); ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past)
Board Member · Since at least Apr 15, 2021
Fred Hassan
Other companies: EyePoint, Inc. (Director · Since at least Sep 3, 2024); Cocrystal Pharma, Inc. (Director · Since at least Apr 20, 2023); BridgeBio Pharma, Inc. (Director · Since at least Aug 17, 2021); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past)
Director · Since Oct 31, 2026
David J Mauro
Other companies: Codiak BioSciences Inc (Chief Medical Officer · May 2, 2022 – Jan 24, 2023 · Past); Prelude Therapeutics Incorporated (Chief Medical Officer · Sep 24, 2020 – Oct 5, 2021 · Past); Advaxis Inc (Chief Medical Officer · Oct 20, 2014 – Dec 31, 2015 · Past)
Chief Medical Officer · Jun 1, 2023 – Nov 15, 2024 · Past
Elaine Sun
Other companies: Dynavax Technologies Corporation (Director · Since at least Dec 10, 2021); Halozyme Therapeutics, Inc. (SVP, Chief Financial Officer · Mar 2, 2020 – Apr 1, 2021 · Past)
Board Member · Since at least Mar 15, 2025
Fred Hassan
Other companies: Cocrystal Pharma, Inc. (Director · Since at least Oct 30, 2025); EyePoint, Inc. (Board Member · Since at least Nov 7, 2024)
Chair of the Board · Since at least Nov 2, 2026
R. Martin Marty Chávez
Other companies: Alphabet Inc (Google) Class C (Board Member · Since at least Jul 11, 2022); Goldman Sachs Group, Inc. (the) (Executive Vice President - CFO · May 1, 2017 – Feb 7, 2018 · Past)
Director · Apr 15, 2021 – Apr 1, 2024 · Past
Terry-Ann Burrell
Other companies: Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Beam Therapeutics Inc. (Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past)
Director · Apr 15, 2021 – Jul 1, 2024 · Past
Ben R Taylor
Other companies: Tyme Technologies Inc (President, CFO · Jul 27, 2017 – May 7, 2020 · Past)
Chief Financial Officer · Since at least Nov 20, 2024
Chris Gibson
Other companies: Pacific Biosciences of California, Inc. (Director · Mar 5, 2026 – Nov 5, 2026 · Past)
Director · Mar 5, 2026 – Nov 5, 2026 · Past
Christopher Gibson
Other companies: Pacific Biosciences of California, Inc. (Director · Since at least Mar 3, 2026)
Director · Since at least Apr 15, 2021
All 30 people
PersonSeat
Dean Li
Other companies: Merck & Company, Inc. (Executive VP & President, MRL · Since at least Jan 1, 2021)
Board Member · Since at least Apr 15, 2021
Michael Secora
Other companies: Iambic Therapeutics, Inc. (Chief Financial Officer and Chief Corporate Development Officer · Since at least Oct 16, 2026)
Chief Financial Officer · Apr 15, 2021 – Nov 15, 2024 · Past
Ben MabeyChief Technology Officer · Since at least Nov 12, 2024
Ben TaylorChief Financial Officer & President Recursion UK · Since at least May 5, 2025
Blake BorgesonBoard Member · Since at least Apr 15, 2021
David HallettChief Scientific Officer · Since at least Jul 8, 2025
Erica FoxChief People and Impact Officer · Since at least Nov 6, 2024
Franziska MichorBoard Member · Since at least Nov 20, 2024
Matt KinnChief Business Officer · Since at least Nov 4, 2026
Najat KhanCEO and President · Since at least Apr 16, 2024
Namandjé BumpusBoard Member · Since at least Mar 15, 2025
Nathan HatfieldChief Legal Officer & Corporate Secretary · Since at least Nov 4, 2026
Ramona DoyleChief Medical Officer · Apr 15, 2021 – May 16, 2022 · Past
Ryan KellyChief Communications Officer · Since at least Jul 29, 2026
Shafique ViraniChief Business Officer · Apr 15, 2021 – Jan 16, 2024 · Past
Sid JainSVP of Clinical Development & Data Science · Since at least Nov 4, 2026
Tina MarriottPresident and COO · Apr 15, 2021 – Nov 15, 2024 · Past
Vicki GoodmanChief Medical Officer · Since at least Oct 26, 2026
Zachary BogueBoard Member · Since at least Apr 15, 2021
Zavain DarBoard Member · Since at least Apr 15, 2021

Open People

Log in to ask 6ix AI your own questions about Recursion Pharmaceuticals, Inc.